Servier has received marketing authorisation from the European Commission (EC) for Tibsovo (ivosidenib tablets) to treat isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukaemia (AML) and IDH1-mutated cholangiocarcinoma.

Tibsovo is an isocitrate dehydrogenase-1 inhibitor indicated to treat IDH1 R132-mutated locally advanced or metastatic cholangiocarcinoma in adult patients who have previously received a minimum of one line of systemic therapy.

Along with azacytidine, the therapy is indicated to treat newly diagnosed IDH1 R132-mutated AML adult patients who are not eligible to receive standard induction chemotherapy.

It is claimed to be the first and only IDH1-targeted therapy to receive approval in Europe.

Servier Global Product Strategy executive vice-president Philippe Gonnard stated: “IDH1 mutations are major drivers of disease progression in acute myeloid leukaemia and cholangiocarcinoma, which are usually diagnosed at an advanced stage, highlighting the urgent need for a targeted therapeutic option.

“The development of new targeted therapies such as Tibsovo, which works differently from traditional chemotherapies, is now providing treatment options that may increase the life expectancy and quality of life for patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This regulatory approval for Tibsovo to treat cholangiocarcinoma was supported by the data obtained from the ClarIDHy Phase III trial.

Findings showed that the median progression-free survival (PFS) for Tibsovo was 2.7 months and for placebo was 1.4 months.

The EC’s approval in AML was supported by data from the multicentre, double-blind, randomised, placebo-controlled, global AGILE Phase III trial.

Tibsovo is approved in the US as monotherapy to treat IDH1-mutant relapsed or refractory AML in adult patients.

In May 2022, it was approved as a monotherapy or along with azacytidine for newly diagnosed IDH1-mutant AML adult patients aged 75 years or above, or those who have comorbidities that prevent the usage of intensive induction chemotherapy.